Difference between revisions of "Methoxsalen (Uvadex)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 17: Line 17:
 
* 1999-02-25: Initial FDA approval for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of [[cutaneous T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment. ''(Based on Edelson et al. 1987)''
 
* 1999-02-25: Initial FDA approval for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of [[cutaneous T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment. ''(Based on Edelson et al. 1987)''
 
* 2013-10-31: Indication revised for extracorporeal administration with the UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of [[cutaneous T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment. ''(No supporting studies are cited)''
 
* 2013-10-31: Indication revised for extracorporeal administration with the UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of [[cutaneous T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment. ''(No supporting studies are cited)''
 
+
==History of changes in EMA indication==
 +
*1958-03-31: EURD
 
==Also known as==
 
==Also known as==
 
Photopheresis systems that methoxsalen is used with may be called UVAR XTS, Therakos, or Therakos Cellex.   
 
Photopheresis systems that methoxsalen is used with may be called UVAR XTS, Therakos, or Therakos Cellex.   
Line 33: Line 34:
  
 
[[Category:FDA approved in 1999]]
 
[[Category:FDA approved in 1999]]
 +
[[Category:EMA approved in 1958]]

Revision as of 23:21, 13 June 2023

General information

Class/mechanism: Psoralen/furocoumarin. Photoactive substance used for palliative photopheresis/extracorporeal phototherapy of cutaneous T-cell lymphoma (CTCL). Exact mechanism of action unknown, but photoactivation of methoxsalen is believed to result in its conjugation and formation of covalent bonds with DNA and possibly proteins. Additions to single strands of DNA and crosslinking of methoxsalen to two strands of DNA occur.[1][2][3]

Route: IV (other formulations of methoxsalen also available in PO & topical forms)
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1999-02-25: Initial FDA approval for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. (Based on Edelson et al. 1987)
  • 2013-10-31: Indication revised for extracorporeal administration with the UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. (No supporting studies are cited)

History of changes in EMA indication

  • 1958-03-31: EURD

Also known as

Photopheresis systems that methoxsalen is used with may be called UVAR XTS, Therakos, or Therakos Cellex.

  • Generic names: 8-MOP, methoxypsoralen
  • Brand names: Ammoidin, Oxsoralen, Oxsoralen-Ultra, Uvadex, Xanthotoxin, Deltasoralen, Dermox, Geralen, Geroxalen, Meladinina, Meladinine, Metoxaleno, Mopsoralen, Puvasoralen, Ultramop

References